Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Kenya National Cancer Treatment Guidelines 2026

Kenya National Cancer Treatment Guidelines 2026 printg@who.int Mon, 02/11/2026 - 08:31 The National Cancer Treatment Guidelines 2026 were developed by the National Cancer Control Program, Division of Cancer and Non-Communicable Diseases, Ministry of Health, Kenya. This revised edition represents a comprehensive update that incorporates the latest global best practices while remaining responsive…

The National Cancer Treatment Guidelines for Kenya, updated in 2026, were meticulously crafted by the National Cancer Control Program, a division under the Ministry of Health. This revised edition is a comprehensive overhaul that reflects the latest global best practices tailored to Kenya's specific epidemiological landscape, resource availability, and existing health system infrastructure.

Noteworthy improvements in this updated guideline include the incorporation of current and advanced chemotherapy regimens, a broader range of pediatric cancer treatment protocols, more precise guidance on managing oncologic emergencies, enhanced survivorship care strategies, and alignment of the financial planning with the current market conditions under Universal Health Coverage.

The Ministry of Health expressed gratitude to the World Health Organization (WHO), AstraZeneca, Roche, CHAI, and the National Cancer Institute of Kenya for their crucial financial and technical support. The guidelines can be accessed in PDF format (13.97 MB) and are specifically categorized under Cancer-related health topics.

Written by urgent.news from WHO Africa's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at afro.who.int →

More in Health & Medicine

GC Biopharma Signs VaxThera Vaccine Deal

Contract Worth About KRW 59.2 Billion Backed by RIGHT Foundation Funding GC Biopharma said on Nov. 2 that it signed a contract with VaxThera, a Colombian vaccine company, for technical support for…

  • GC Biopharma signs KRW 59.2 billion deal with VaxThera for influenza vaccine production.
  • GC Biopharma supplies bulk drug substance and process technology support.
  • VaxThera manages filling, packaging, quality control, and local distribution.

More from Monday 2 November →